Market research
ABUS Arbutus Biopharma Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- 6.59
- Analyst target
- 5.5449
- Dividend yield
- Not available
- Beta
- 0.6
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA03879J1003
- Market cap
- 1B
- P/E ratio
- 6.59
- Analyst target
- 5.5449
- Dividend yield
- Not available
- Beta
- 0.6
About
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ABUS discussion.
5 years, 4 months ago
Arbutus Biopharma Corporation is currently in a long term downtrend where the price is trading 15.7% below its 200 day moving average.
From a valuation standpoint, the stock is 97.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 37.2.
Arbutus Biopharma Corporation's total revenue rose by 47.5% to $2M since the same quarter in the previous year.
Its net income has increased by 30.9% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 13.1% to $-15M since the same quarter in the previous year.
Based on the above factors, Arbutus Biopharma Corporation gets an overall score of 3/5.